VTVT
vTv Therapeutics Inc - Ordinary Shares - Class A

14,836
Loading...
Loading...
News
all
press releases
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR...
PR Newswire·9mo ago
News Placeholder
More News
News Placeholder
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON...
PR Newswire·1y ago
News Placeholder
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE...
PR Newswire·1y ago
News Placeholder
vTv Therapeutics Inc. (NASDAQ:VTVT) Sees Large Growth in Short Interest
vTv Therapeutics Inc. (NASDAQ:VTVT Get Free Report) saw a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 57,200 shares, a growth...
Zolmax·1y ago
News Placeholder
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT PR Newswire WESTON, Fla...
PR Newswire·1y ago
News Placeholder
vTv Therapeutics expects cash to fund operations through Phase 3 study data
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Recently completed $51 million PIPE from healthcare-focused institutional investors and the JDRF T1D Fund.Company's first Phase 3 clinical trial of cadisegliatin (TTP399), an oral adjunctive therapy...
Globe Newswire·2y ago
News Placeholder
vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
HIGH POINT, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an...
Globe Newswire·2y ago
News Placeholder
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
HIGH POINT, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an...
Globe Newswire·2y ago
News Placeholder
12 titres de soins de sant en mouvement lors de la pr -ouverture le 28/02/2024
Gagnants Le titre vTv Therapeutics (NASDAQ:VTVT) a grimp mercredi de 57,06% 13,35 dollars lors de la session pre-market. L'action Applied Therapeutics (NASDAQ:APLT) a mont de 52,32% 8,50...
Benzinga·2y ago

Latest VTVT News

View

Advertisement. Remove ads.

Advertisement. Remove ads.